Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cross Country Healthcare (CCRN) EBITDA (2016 - 2025)

Cross Country Healthcare (CCRN) has disclosed EBITDA for 16 consecutive years, with -$83.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 2084.96% year-over-year to -$83.0 million, compared with a TTM value of -$95.0 million through Dec 2025, down 549.95%, and an annual FY2025 reading of -$95.0 million, down 549.95% over the prior year.
  • EBITDA was -$83.0 million for Q4 2025 at Cross Country Healthcare, down from -$4.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $77.6 million in Q4 2021 and bottomed at -$83.0 million in Q4 2025.
  • Average EBITDA over 5 years is $14.2 million, with a median of $12.2 million recorded in 2021.
  • The sharpest move saw EBITDA skyrocketed 6249.87% in 2021, then crashed 2084.96% in 2025.
  • Year by year, EBITDA stood at $77.6 million in 2021, then crashed by 50.02% to $38.8 million in 2022, then plummeted by 76.67% to $9.0 million in 2023, then plummeted by 141.97% to -$3.8 million in 2024, then plummeted by 2084.96% to -$83.0 million in 2025.
  • Business Quant data shows EBITDA for CCRN at -$83.0 million in Q4 2025, -$4.9 million in Q3 2025, and -$6.7 million in Q2 2025.